The Value of Ocular Disease Models
The eye offers unique advantages for disease modeling and therapeutic development:
Accessibility
Direct visualization of disease progression through fundoscopy and OCT. Non invasive monitoring of structural and functional changes.
Compartmentalization
Immune privilege and blood retinal barrier create defined microenvironment. Local delivery enables high drug concentrations with minimal systemic exposure.
Gene Therapy Success
The eye has been a pioneering tissue for gene therapy, with approved treatments for inherited retinal diseases. Mouse models support preclinical development.
Translational Relevance
Despite anatomical differences, mouse models have successfully predicted human responses to multiple therapeutic approaches.
Retinal Degenerative Diseases
Retinitis Pigmentosa
Inherited rod cone dystrophies affecting 1 in 4000 individuals:
Rhodopsin Mutations
RHO is the most commonly mutated gene in autosomal dominant RP. Point mutation knockins model specific patient variants.
PDE6 Mutations
rd1 and rd10 mice carry mutations in Pde6b and develop rapid photoreceptor degeneration. Widely used for therapy development.
RPGR and RP2
X linked RP models for ciliopathy associated retinal degeneration.
Gene Therapy Models
Humanized models enable testing of human specific gene therapy vectors.
Leber Congenital Amaurosis & Cone Dystrophies
Severe early onset retinal dystrophies:
RPE65 Models
RPE65 knockout and knockin mice model LCA2, the first genetic eye disease treated with gene therapy.
CEP290, GUCY2D, CRB1
Additional LCA genes with available mouse models.
Achromatopsia Models
CNGA3 and CNGB3 mutations cause complete color blindness. Knockout and knockin models available.
Cone Rod Dystrophies
Models for conditions where cones degenerate before or alongside rods.
Glaucoma
Progressive optic neuropathy and leading cause of irreversible blindness:
Intraocular Pressure Models
Microbead Occlusion
Magnetic or polystyrene microbeads injected into anterior chamber obstruct aqueous outflow, elevating IOP.
Laser Photocoagulation
Laser treatment of trabecular meshwork induces scarring and elevated IOP.
Genetic IOP Elevation
Mutations affecting outflow pathways (myocilin, CYP1B1) can elevate IOP.
Normal Tension Glaucoma & Optic Nerve Injury
GLAST Knockout
Glutamate transporter deficiency causes RGC loss without elevated IOP.
DBA/2J
Develops pigmentary glaucoma with RGC loss and optic nerve degeneration.
Optic Nerve Crush
Mechanical injury induces RGC death and axon degeneration.
Ischemia Reperfusion
Models acute ischemic injury to the optic nerve.
Age Related Macular Degeneration
Leading cause of vision loss in elderly populations:
Dry AMD Models
ABCA4 Knockout
Accumulation of lipofuscin and A2E in RPE.
CFH Variants
Complement factor H variants increase AMD risk. Knockin models enable pathway analysis.
Oxidative Stress Models
Light damage, sodium iodate, and other oxidative insults model geographic atrophy.
Wet AMD Models
Laser Induced CNV
Choroidal neovascularization induced by laser photocoagulation of Bruch membrane.
VEGF Overexpression
Transgenic or viral VEGF expression drives neovascularization.
Genetic Predisposition
Complement, lipid metabolism, and other pathway modifications affect CNV susceptibility.
Diabetic Retinopathy
Microvascular complications of diabetes affecting the retina:
db/db Mice
Leptin receptor deficient mice develop diabetes and retinal vascular changes.
Akita Mice
Ins2 mutation causes insulin deficient diabetes with retinal pathology.
STZ Induced Diabetes
Streptozotocin treatment destroys beta cells. Combined with genetic modifications for mechanistic studies.
Retina Specific Targeting
Cell type-specific Cre drivers for targeted gene manipulation:
| Cell Type | Cre Driver | Application |
|---|---|---|
| Photoreceptor Specific | Rhodopsin Cre (Rho Cre) | Targets rods. Cone opsin Cre (Opn1mw Cre) targets cones. |
| RPE Specific | VMD2 Cre (Best1 Cre) | Targets retinal pigment epithelium. |
| RGC Specific | Thy1 Cre | Ganglion cell drivers for glaucoma studies. |
| Muller Glia | GFAP Cre or Rlbp1 Cre | For Muller cell targeting. |
Phenotyping Ocular Models
Structural Assessment
- Optical Coherence Tomography (OCT):In vivo imaging of retinal layers. Quantify photoreceptor, RGC, and other layer thickness.
- Fundus Photography:Document fundus appearance, vascular changes, and pathology.
- Histology:Detailed layer by layer analysis. Immunohistochemistry for cell type markers.
Functional Assessment
- Electroretinography (ERG):Electrical response to light stimulation. a wave (photoreceptors), b wave (bipolar cells), photopic negative response (RGCs).
- Visual Acuity:Optokinetic tracking for behavioral measure of vision.
- Pupillary Light Reflex:Assess melanopsin positive RGC function.
Therapeutic Applications
Selected Publications in Ophthalmology Research
According to PubMed, recent publications demonstrate the utility of genetically engineered mouse models in ophthalmology research:
Xia F et al. (2025).
CXCR3 Deficiency Alleviates Retinal Ganglion Cell Loss by Regulating Neuron Astrocyte Communication in a Mouse Model of Glaucoma. ↗Investigative Ophthalmology & Visual Science 66(3): 27
Hoppe C et al. (2025).
The alternative complement pathway drives neuroinflammation and neurodegeneration in mouse models of glaucoma and optic nerve injury. ↗Neurobiology of Disease 210: 106927
What Researchers Say
“The Hephaestin flox model ingenious has made for us has been great. It has helped generate eight research publications.”
— Joshua Dunaief, PhD, MD
University of Pennsylvania
Start Your Ophthalmology Model Project
Ready to discuss custom mouse models for your eye disease research? Our scientific team provides complimentary consultation to help you design the optimal model for your ophthalmology research goals.